Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Psychiatric Ratings using Intermediate Stratified Markers 2

Description du projet

Nouveaux biomarqueurs permettant de classer les troubles neuropsychiatriques

La classification des troubles neuropsychiatriques tels que la schizophrénie, dont la biologie fondamentale demeure relativement méconnue, dépend essentiellement des biomarqueurs de neuroimagerie et des critères d’évaluation clinique. L’utilisation de biomarqueurs quantitatifs favoriserait non seulement la classification des maladies, mais aussi les efforts en matière de développement de médicaments. Le projet PRISM 2, financé par l’UE, tirera parti des connaissances générées par son prédécesseur, PRISM 1, consacré aux biomarqueurs de diagnostic et de fonctionnement social pour la schizophrénie et la maladie d’Alzheimer, et visera à les étendre aux troubles dépressifs majeurs. Son objectif est d’identifier des biomarqueurs fiables pour contribuer au diagnostic et au traitement personnalisé des troubles neuropsychiatriques.

Objectif

The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.

Coordinateur

RIJKSUNIVERSITEIT GRONINGEN
Contribution nette de l'UE
€ 1 024 422,50
Adresse
Broerstraat 5
9712CP Groningen
Pays-Bas

Voir sur la carte

Région
Noord-Nederland Groningen Overig Groningen
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 1 624 422,50

Participants (17)